VOPROSY TERAPII INTERSTITsIAL'NOGO PORAZhENIYa LEGKIKh PRI NEKOTORYKh SISTEMNYKh AUTOIMMUNNYKh ZABOLEVANIYaKh


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Systemic autoimmune diseases (SAD) include a heterogeneous group of immune-mediated inflammatory diseases characterized by the development of multi-organ failure. Patients with SAD can experience interstitial lung disease (ILD). High-resolution computed tomography of the lungs and pulmonary function test play a leading role in the diagnosis of ILD. To date, despite the progress in addressing issues of pathogenesis and diagnosis of ILD in SAD, there is no effective immunomodulatory therapy for ILD-SAD. The therapy of ILD is aimed to the suppressing immune inflammatory process. This article discusses the effectiveness of the immunosuppressive therapy in some SAD.

Full Text

Restricted Access

References

  1. Castelino F.V., Goldberg H., Dellaripa P.F. American College of Rheumatology Annual Meeting. San Francisco, CA; 2008. The impact of rheumatologic evaluation on the management of patients with interstitial lung disease (ILD) [abstract 637].
  2. Steen V.D., Lanz J.K. Jr., Conte C., et al. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum. 1994; 37: 1290-96.
  3. Akesson A., Scheja A., Lundin A., Wollheim F.A. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum. 1994; 37: 729-35.
  4. White B., Moore W.C., Wigley F.M., et.al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern. Med. 2000; 132: 947-54.
  5. Tashkin D.P., Elashoff R., Clements P.J., et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am. J. Respir. Crit. Care Med.2007; 176: 1026-34.
  6. Hoyles R.K., Ellis R.W., Wellsbury J., et al. A multicenter, prospective, randomized, doubleblind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006; 54: 3962-70.
  7. Zamora A.C., Wolters P.J., Collard H.R., et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med. 2008; 102: 150-55.
  8. Gerbino A.J., Goss C.H., Molitor J.A. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest. 2008; 133: 455-60.
  9. Dheda K., Lalloo U.G., Cassim B, Mody G.M. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin. Rheumatol. 2004; 23: 306-09.
  10. Berezne A., Ranque B., Valeyre D., et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J. Rheumatol. 2008; 35: 1064-72.
  11. Silver R.M., et al. Endothelin and scleroderma lung disease. Rheumatology (Oxford). 2008; 47(Suppl 5): v25-v26.
  12. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.2008; 177: 75-81.
  13. An Of cial ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. Am. J. Respir. Crit. Care Med. 2011; 183: 788-824.
  14. Nagai S., Hamada K., Shigematsu M., et al. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern. Med. 2002; 41: 1118-23.
  15. Schachna L., Medsger T.A. Jr., Dauber J.H., et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum. 2006; 54: 3954-61.
  16. Massad M.G., Powell C.R., Kpodonu J., et al. Outcomes of lung transplantation in patients with scleroderma. World J. Surg. 2005; 29: 1510-15.
  17. Bouros D., Wells A.U., Nicholson A.G., et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am. J. Respir. Crit. Care Med. 2002; 165: 1581-86.
  18. Wells A.U., Cullinan P., Hansell D.M., et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am. J. Respir. Crit. Care Med. 1994; 149: 1583-90.
  19. Daniels C.E., Lasky J.A., Limper A.H., et al. Imatinib treatment for IPF: randomized placebo controlled trial results. Am. J. Respir. Crit. Care Med. 2009; 181: 604-10.
  20. Van Daele P.l., Dik W.A., Thio H.B., et al. Is imatinib mesylate a promising drug in systemic sclerosis? Arthritis Rheum. 2008; 58: 2549-52.
  21. Sfikakis P.P., Gorgoulis V.G., Katsiari C.G., et al. Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford). 2008; 47: 735-37.
  22. McDonagh J., Greaves M., Wright A.R., et al. High resolution computed tomography of the lungs in patients with rheumatoid arthritis and interstitial lung disease. Br. J. Rheumatol. 1994; 33: 118-22.
  23. Lee H.K., Kim D.S., Yoo B., et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 2005; 127: 2019-27.
  24. Turesson C., Matteson E.L., Colby T.V., et al. Increased CD4+T cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis. Arthritis Rheum. 2005; 52: 73-79.
  25. Lynch J.P., Saggar R., Weigt S.S., et al. Usual interstitial pneumonia. Semin Respir. Crit. Care Med.2006; 27: 634-651.
  26. Demedts M., Behr J., Buhl R., et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2005; 353: 2229-42.
  27. Saketkoo L.A., Espinoza L.R. Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug. Arch Intern. Med. 2008; 168: 1718-19.
  28. Chen I.J., Jan Wu Y.J., Lin C.W., et al. Interstitial lung disease in polymyositis and dermatomyositis. Clin. Rheumatol. 2009; 28: 639-646.
  29. Hayashi S., Tanaka M., Kobayashi H., et al. High-resolution computed tomography characterization of interstitial lung diseases in polymyositis/dermatomyositis. J. Rheumatol. 2008; 35: 260-69.
  30. Tillie-Leblond I., Wislez M., Valeyre D., et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax. 2008; 63: 53-59.
  31. Kubo M., Ihn H., Yamane K., et al. Serum KL-6 in adult patients with polymyositis and dermatomyositis. Rheumatology (Oxford). 2000; 39: 632-36.
  32. Fujisawa T., Suda T., Nakamura Y., et al. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol. 2005; 32: 58-64.
  33. Yamasaki Y., Yamada H., Yamasaki M., et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford). 2007; 46: 124-30.
  34. Ochi S., Nanki T., Takada K., et al. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. Clin. Exp. Rheumatol. 2005; 23: 707-10.
  35. Wilkes M.R., Sereika S.M., Fertig N., et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum. 2005; 52: 2439-46.
  36. Sem M., Molberg O., Lund M.B., Gran J.T. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford). 2009; 48: 968-71.
  37. Rios Fernandez R., Callejas Rubio J.L., Sanchez Cano D., et al. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin. Exp. Rheumatol. 2009; 27: 1009-16.
  38. Ito I., Nagai S., Kitaichi M., Nicholson A.G., et al. Pulmonary manifestations of primary Sjogren's syndrome: a clinical, radiologic, and pathologic study. Am. J. Respir. Crit. Care Med. 2005; 171: 632-38.
  39. Parambil J.G., Myers J.L., Lindell R.M., et al. Interstitial lung disease in primary Sjogren syndrome. Chest.2006; 130: 1489-95. doi: 10.1378/chest.130.5.1489.
  40. Pego-Reigosa J.M., Medeiros D.A., Isenberg D.A. Respiratory manifestations of systemic lupus erythematosus: old and new concepts. Best Pract. Res. Clin. Rheumatol. 2009; 23: 469-80.
  41. Lim S.W., Gillis D., Smith W., et al. Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports. Intern. Med J. 2006; 36: 260-62.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies